Protein Expression Market Report 2025

This Protein Expression market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The protein expression market size has grown rapidly in recent years. It will grow from $3.58 billion in 2024 to $3.98 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to scientific research, biopharmaceutical development, biotechnology advancements, drug discovery and development, healthcare industry growth.

The protein expression market size is expected to see rapid growth in the next few years. It will grow to $6.57 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to personalized medicine, biosimilars market, drug repurposing, regulatory support, precision agriculture. Major trends in the forecast period include cell-free expression systems, crispr-cas9 for gene editing, sustainable bioprocessing, contract research and manufacturing, multi-modal expression platforms.

The protein expression market is experiencing significant growth driven by the increasing demand for biologics in addressing various genetic disorders and chronic diseases. Biologics encompass medicines derived from living organisms or containing components of living organisms, such as proteins, tissues, genes, and vaccines. The growing utilization of biologics, including therapeutic proteins, for the treatment of chronic conditions like cancer, cardiovascular diseases, and genetic disorders, is fostering the need for protein expression devices and equipment. For example, as of September 2022, the World Health Organization reported that approximately 74% of global annual deaths, which amounted to 41 million, were due to non-communicable diseases (NCDs) or chronic diseases. Consequently, the surging demand for biologics is propelling the protein expression market. Additionally, the biologics market held a substantial share, exceeding a quarter of the entire pharmaceutical market in 2020, as reported by analysts. The global biologics market is anticipated to grow by 14.7% during 2021-2023.

The growth of the protein expression market is expected to be driven by increasing government funding for research in the biopharmaceutical industry. Government funding for research in this sector refers to the financial resources provided by governments to companies and institutions engaged in developing new drugs and therapies. Such funding supports the protein expression market by fostering the advancement of innovative protein expression technologies and lowering the costs associated with protein production. For example, in March 2024, the Food & Drug Administration (FDA), a US-based federal agency, announced cooperative agreements offering up to three awards totaling $600,000 in fiscal year (FY) 2024 and up to five awards amounting to $1,000,000 in FY 2025. These funding initiatives are part of the FDA’s ongoing efforts to collect data on antimicrobial use in animals. Consequently, increasing government funding for biopharmaceutical research is propelling the growth of the protein expression market.

The protein expression market's growth may encounter hindrances due to government regulations concerning protein therapeutics and biologics production. These regulations impose rigorous preclinical and clinical trial requirements for biologics, leading to lengthy approval processes, with a primary focus on ensuring the health and safety of individuals. Marketing and distribution of biologics, which includes insulin, hormones, therapeutic antibodies, and vaccines, is contingent on successful completion of these clinical trials, which are often protracted, costly, and uncertain. For instance, the FDA stipulates that the approval of new biologics typically entails 10 to 12 months, with firms required to provide annual reports on the status of clinical safety, clinical efficacy, clinical pharmacology, and nonclinical toxicology studies.

Major players operating in the protein expression market are placing a greater emphasis on introducing next-generation solutions, such as the Visium CytAssist Gene and Protein Expression Assay, to optimize their market revenues. These next-generation solutions leverage advanced technologies and techniques to enhance the speed, accuracy, and efficiency of protein expression. In May 2023, 10x Genomics Inc., a US-based biotechnology company, launched the Visium CytAssist Gene and Protein Expression Assay, designed to enable researchers to explore protein expression patterns within the human immune system. The Visium approach distinguishes itself by performing H&E (Hematoxylin and Eosin) staining before applying any chemical treatments to tissue sections, facilitating three-dimensional spatial analysis on the same sample while preserving tissue morphology. This approach permits the collection of protein and whole transcriptome gene expression, along with histological analysis in a single experiment from a single tissue section.

The companies within the industry are increasingly incorporating Microfluidics technology into protein expression tests to reduce time, labor, and costs while improving accuracy and performance. Microfluidics technology offers enhanced analytical capabilities compared to traditional macroscale instruments. It is employed for assessing protein expression on cells and optimizing results related to protein expression. Therapeutics-on-a-chip (TOC) leverages microfluidic platforms to synthesize proteins in point-of-care settings, reducing the expenses associated with storing and transporting therapeutic proteins. Several companies, including MissionBio, NanoCellect Biomedical, RainDance Technologies, and Sphere fluidics, have implemented this technology in protein expression tests.

Protein expression is the biological process through which proteins are created, modified, regulated, and managed within living organisms based on the directives of the host cell. In the realm of protein research, protein expression may also encompass the laboratory techniques essential for producing proteins.

The primary product categories related to protein expression consist of reagents, competent cells, expression vectors, services, and instruments. Reagents are substances or compounds introduced into a system to trigger a chemical reaction or to ascertain whether a reaction has occurred. Protein expression takes various forms, including yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, and cell-free expression, all of which find applications in therapeutic, industrial, and research settings. Diverse end users of these protein expression products and services include pharmaceutical and biotechnology companies, academic research institutions, and contract research organizations.

The protein expression market research report is one of a series of new reports that provides protein expression market statistics, including protein expression industry global market size, regional shares, competitors with a protein expression market share, detailed protein expression market segments, market trends and opportunities, and any further data you may need to thrive in the protein expression industry. This protein expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the protein expression market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., New England Biolabs Inc., Promega Corporation, Qiagen NV, Takara Bio Inc., Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton, Dickinson & Company, Lonza Group Ltd., Geneva Biotech LLC, Viva Biotech Holdings, Sengenics LLC, ARTES Biotechnology GmbH, Addgene Inc., Profacgen, ProteoGenix Inc., Peak Proteins Ltd., Domainex Ltd., Jena Bioscience GmbH, EMD Millipore Corporation, Oxford Expression Technologies Ltd., Creative Biolabs Inc., Abnova Taiwan Corp, Accelagen Inc.

North America was the largest region in the protein expression market in 2024. Western Europe was the second largest region in the protein expression market. The regions covered in the protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The protein expression market includes revenue earned by instruments, expression kits, and systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.